STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2019

Mar 27, 2019

March 27, 2019

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza , Bandra‐Kurla Complex Bandra (E) Mumbai ‐ 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached press release issued by the Company titled:

“Strides receives USFDA approval for its greenfield oral dosage facility in Singapore”

Thanks and Regards

For Strides Pharma Science Limited

==> picture [128 x 52] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [85 x 83] intentionally omitted <==

Strides Pharma Science Limited

(Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Press Release

March 27, 2019

Strides receives USFDA approval for its greenfield oral dosage facility in Singapore

Facility to provide growth capacities for regulated markets of US, Australia, UK and Europe and help expand manufacturing base

Bangalore, March 27, 2019 ‐ Strides Pharma Science Limited (Strides) today announced that it has received USFDA approval for its greenfield oral dosage facility in Singapore.

Singapore oral dosage facility – For growth capacities

• With the commercialization of its manufacturing facility in Singapore, Strides will join the league of global pharmaceutical companies having a Manufacturing and Research and Development footprint in Singapore

• The facility will complement Strides’ existing manufacturing base and will help meet increased demand from its fast‐growing regulated markets business across US, Australia, UK and Europe

• Singapore is also amongst the list of designated countries under the Trade Agreements Act (TAA) making it eligible to supply goods under Federal Supply Schedule (FSS) contracts in the US. The manufacturing facility in Singapore will enable the Company to tap opportunities under various federal government procurement programs including procurements administered by Department of Veterans Affairs (VA).

• The facility operating at its peak capacity will produce ~1.4 billion tablets and hard gelatin capsules

• The facility has been built with emphasis on automation in production and quality control laboratories and has fully integrated manufacturing and packing lines

• The facility has already been approved by Health Science Authority (HSA) Singapore and Therapeutic Goods Administration (TGA) Australia

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India‐ Bangalore (two sites), Pondicherry and Chennai, Singapore, Italy‐ Milan, and Kenya‐ Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

Strides PR Consultancy Badree Komandur, Fortuna PR Executive Director ‐ Finance K Srinivas Reddy: +91 90005 27213 +91 80 6784 0747 srinivas@fortunapr.com K Priya: +91 95354 25418 priya@fortunapr.com Investor Relations: Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791 Email: Sandeep.baid@strides.com Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN : L24230MH1990PLC057062 Regd. Office: 201, ‘Devavrata’, Sector ‐ 17, Vashi, Navi Mumbai ‐ 400 703 Corp. Office: Strides House, Bannerghatta Road, Bangalore ‐ 560076